New Jersey is one step closer to establishing a statewide Parkinson’s disease (PD) registry following a recent vote by the Senate Budget and Appropriations Committee. Sponsored by senators Raj Mukherji and Angela McKnight, the bill S2339 aims to improve understanding of Parkinson’s disease across the state and enhance research efforts to develop more effective treatments.
“Parkinson’s disease is a highly complex condition that affects individuals in different ways,” said Sen. Mukherji (D-Hudson). “This registry will allow us to gather important data that can lead to breakthrough treatments, help clinicians provide more targeted care, and ultimately offer patients and families new hope.”
Fast Growing Disorder
Parkinson’s disease is the second most common neurodegenerative disorder and is the fastest-growing neurological ailment globally. Given the disease’s varied symptoms and progression in different patients, creating a statewide registry is seen as a critical tool for both clinicians and researchers.
Under the proposed legislation, healthcare providers would be required to report cases of PD and Parkinsonism — an umbrella term for disorders affecting movement — to the Department of Health (DOH). The DOH would then collect and maintain the data to improve patient care and advance medical research.
“This registry will not only benefit healthcare providers, but it will also serve as a vital tool for public health agencies,” said Sen. McKnight (D-Hudson). “By streamlining and expanding access to information about Parkinson’s disease, we can raise public awareness and support the development of critical public health interventions.”
Data Helps Researchers
The registry, housed within the DOH, will securely collect information on PD cases across New Jersey and will be made available to researchers and other health organisations for continued study. Patients will also have the option to opt out, with only the incidence of their diagnosis being reported.
In addition, the bill calls for the creation of an advisory council to guide the development of the registry, determine the types of data to be collected, and assist with the overall implementation of the program. The DOH would also be required to release an annual report summarizing the data and making it publicly available.
Registry Part of Broader Effort
New Jersey’s proposed registry is part of a broader effort happening in other states to improve tracking and understanding of the disease. The hope is that this information could ultimately lead to more effective treatments and public health strategies.
Examples of state-level registries include:
- California Parkinson’s Disease Registry (CPDR): Requires mandatory reporting of all PD cases in the state.
- Utah Parkinson’s Disease Registry (UPDR): Was launched in response to Utah designating PD as a reportable disease.
- Nebraska Parkinson’s Disease Registry: Was the first statewide registry in the United States, though it has experienced funding issues in the past.
- New York: Has passed legislation to establish a research registry.
Key Functions and Goals of Registries
There are approximately one million people with Parkinson’s disease (PD) living in the US, according to epidemiological studies and the American Parkinson Disease Association. That means approximately 1 in 336 people is living with PD. That number has increased in the past decades and will continue to increase. There is a new diagnosis every six minutes, and approximately 90,000 new diagnoses in the US per year. A registry can:
- Track disease rates: Establish accurate counts of the number of people with Parkinson’s disease (incidence and prevalence) in a specific area.
- Support research: Provide a database of information for researchers to study risk factors, genetic and environmental influences, and disease progression.
- Inform public health policy: Help health systems plan for care, improve outreach, and develop evidence-based programs.
- Facilitate clinical trial recruitment: Act as a resource for identifying and recruiting participants for future research studies.